中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
硬脂酰胺 | stearamide | 124-26-5 | C18H37NO | 283.498 |
A receptor peroxisome proliferator activated receptor-gamma was targeted by series of new fatty acid chemical entities (M1- M22) which was designed, synthesized and characterized by spectral analysis. Metabolites molecular properties were calculated using Lipinski’s rule of five using molinspiration online software. Docking studies were done on co-crystallized protein structure of PPAR γ, PDB-1FM9 showing M15, M17 and M8 to be best located in the active sites with scores -10.43, -10.21 and -10.00 respectively. The free binding energy estimation was done using model of Maestro 9.0 (Schrodinger) and lies between -80.15 to -61.26 kcal/mol which is significant as compared to that of standard (-48.58 Kcal/mol). Nine best docked derivatives were evaluated in-vivo for oral glucose tolerance and antihyperglycemic activity by streptozotocin induced diabetes model and M15 exhibited most promising antidiabetic activity more than the standard glibenclamide. The promising results encourage future investigation on fatty acids for development of active compounds.
靶向过氧化物酶体增殖激活受体-γ(PPAR-γ)的一系列新脂肪酸化学实体(M1-M22)被设计、合成并通过光谱分析进行了表征。利用molinspiration在线软件根据利宾斯基五规则计算了代谢物的分子特性。在PPAR γ的共晶蛋白结构PDB-1FM9上进行了分子对接研究,结果显示M15、M17和M8在活性位点定位最佳,得分分别为-10.43、-10.21和-10.00。使用Maestro 9.0(Schrodinger)模型进行了自由结合能估计,其值介于-80.15至-61.26千卡/摩尔之间,与标准值(-48.58千卡/摩尔)相比具有显著性。九个最佳对接衍生物在体内通过链脲佐菌素诱导的糖尿病模型评估了口服葡萄糖耐量及抗高血糖活性,其中M15显示出比标准药物格列本脲更具有前景的抗糖尿病活性。这些有希望的结果鼓励未来对脂肪酸进行深入研究,以开发出活性化合物。